Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is © The Royal Society of Chemistry 2015

## **Supporting Information**

## Molecular simulations studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-

## pyrimidines in complexes with CDK2 and CDK7

Tahir Ali Chohan, Hai-Yan Qian, You-Lu Pan, and Jian-Zhong Chen\*

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058,

China

\* Corresponding Author: email: chjz@zju.edu.cn (J.-Z. Chen)

Docking	$\Delta G_{\mathrm{exp}}$	CScore <sup>a</sup>	Crash	Polar	G score <sup>d</sup>	PMF	D score <sup>f</sup>	Chem	Amino acid
complex			score <sup>b</sup>	score <sup>c</sup>		score <sup>e</sup>		score <sup>g</sup>	interaction
CDK2-CP1	-13.66	7.20	-1.02	1.89	-249.57	-62.04	-150.91	-29.01	Leu83, Lys89, Asp86
CDK7-CP1	-8.27	4.49	-1.02	2.15	-136.05	-43.39	-108.54	-24.65	Met94
CDK7-CP2	-9.79	5.41	-1.10	1.68	-200.73	-24.64	-200.73	-34.87	Met94
CDK7-CP3	-11.85	5.55	-0.47	1.82	-110.04	-66.02	-193.54	-25.25	Met94

Table S1. Surflex score of docked ligand CP1 for CDK2 and CP1-3 for CDK7

<sup>*a*</sup>**CScore** is a consensus scoring which uses multiple types of scoring functions to rank the affinity of ligands, <sup>*b*</sup>**Crash**score revealing the inappropriate penetration into the binding site, <sup>*c*</sup>**Polar** region of the ligand, <sup>*d*</sup>**G-score** showing hydrogen bonding, complex (ligand-protein), and internal (ligand-ligand) energies, <sup>*e*</sup>**PMF-score** indicating the Helmholtz free energies of interactions for protein-ligand atom pairs (Potential of Mean Force, PMF), <sup>*f*</sup>**D-score** for charge and van der Waals interactions between the protein and the ligand, <sup>*g*</sup>**Chem-score** points for hydrogen bonding, lipophilic contact, and rotational entropy, along with an intercept term.



**Figure S1.** Comparison of binding modes of docked ligand with their starting conformations. **(A)** Superimposition of the docked ligand CP1 (Purple) and experimental conformation of CDK2 (Cyan). **(B)** Superimposition of the docked ligand CP1 (Purple) and experimental conformation of CP3 in the active site of CDK2 (Cyan). **(C)** Alignment of docked compounds CP1 (Purple), CP2 (Green) and CP3 (Cyan) within the active site of CDK7. The main residues constituting the active site are identified with a three letter representation. **(D)** The average means RMSD using bars chat.

CDK1	MEDYTKIEK <mark>IGE</mark> GTYGV <mark>V</mark> YKGRHKTTGQVV <mark>A</mark> M <mark>K</mark> KIRLESEEEGVPSTA	48
CDK2	MENFQKVEK <mark>IGE</mark> GTYGV <mark>V</mark> YKARNKLTGEVV <mark>A</mark> L <mark>K</mark> KIRLDTETEGVPSTA	48
CDK3	FCFPGSSVAMDMFQKVEK <mark>IGE</mark> GTYGV <mark>V</mark> YKAKNRETGQLV <mark>A</mark> L <mark>K</mark> KIRLDLEMEGVPSTA	57
CDK4	MATSRYEPVAE <mark>IGV</mark> GAYGT <mark>V</mark> YKARDPHSGHFV <mark>A</mark> L <mark>K</mark> SVRVPNGGGGGGGLPIST	53
CDK7	-MALDVKSRAKRYEKLDF <mark>LGE</mark> GQFAT <mark>V</mark> YKARDKNTNQIV <mark>A</mark> I <mark>K</mark> KIKLGHRSEAKDGINRTA	59
	· : : :* * :***.:. :**:*.:: *: ::	
CDK1	IREISLLKELRHPNIVSLQDVLMQDSRLYLI <mark>FEFLSMD</mark> LK <mark>K</mark> YLDSIPPGQYM	100
CDK2	IREISLLKELNHPNIVKLLDVIHTENKLYLV <mark>FEFLHQD</mark> LK <mark>K</mark> FMDASA-LTGI	99
CDK3	IREISLLKELKHPNIVRLLDVVHNERKLYLV <mark>FEFLSQD</mark> LK <mark>K</mark> YMDSTP-GSEL	108
CDK4	VREVALLRRLEAFEHPNVVRLMDVCATSRTDREIKVTLV <mark>FEHVDQD</mark> LR <mark>T</mark> YLDKAP-PPGL	112
CDK7	LREIKLLQELSHPNIIGLLDAFGHKSNISLV <mark>FDFMETD</mark> LE <mark>V</mark> IIKDNSLVL	109
	:**: **:. : ***:: * *: *:*:.: **. :. :	
CDK1	DSSLVKSYLYQILQGIVFCHSRRVLHRDLKP <mark>QNLLI</mark> DDKGTIKL <mark>ADF</mark> GLARAFGIPIRVY	160
CDK2	PLPLIKSYLFQLLQGLAFCHSHRVLHRDLKP <mark>QNLLI</mark> NTEGAIKL <mark>ADF</mark> GLARAFGVPVRTY	159
CDK3	PLHLIKSYLFQLLQGVSFCHSHRVIHRDLKP <mark>QNLLI</mark> NELGAIKL <mark>ADF</mark> GLARAFGVPLRTY	168
CDK4	PAETIKDLMRQFLRGLDFLHANCIVHRDLKP <mark>ENILV</mark> TSGGTVKL <mark>ADF</mark> GLARIYSYQM-AL	171

CDK7 TPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAY 169 :\* : \*:\*: : \* . ::\*\*\*\*\*\*:\*: \*.:\*\*\*\*\*\*\*: ...

	* *** ***:**: * * * *******************	
CDK7	${\tt TH} QVV{\tt TR} {\tt W} {\tt RAPELL} {\tt F} {\tt G} {\tt RM} {\tt G} {\tt V} {\tt G} {\tt V} {\tt M} {\tt W} {\tt A} {\tt V} {\tt G} {\tt C} {\tt L} {\tt A} {\tt E} {\tt L} {\tt L} {\tt R} {\tt V} {\tt F} {\tt L} {\tt P} {\tt G} {\tt S} {\tt D} {\tt L} {\tt D} {\tt Q} {\tt L} {\tt T} {\tt I} {\tt F} {\tt E} {\tt L} {\tt L} {\tt A} {\tt A} {\tt A} {\tt A} {\tt C} {\tt L} {\tt A} {\tt E} {\tt L} {\tt L} {\tt R} {\tt V} {\tt P} {\tt F} {\tt L} {\tt P} {\tt G} {\tt D} {\tt S} {\tt D} {\tt L} {\tt D} {\tt Q} {\tt L} {\tt T} {\tt F} {\tt E} {\tt L} {\tt A} {\tt A}$	229
CDK4	TPVVVTLWYRAPEVLLQS-TYATPVDMWSVGCIFAEMFRRKPLFCGNSEADQLGKIFDLI	230
CDK3	${\tt THEVVTLWYRAPEILLGSKFYTTAVDIWSIGCIFAEMVTRKALFPGDSEIDQLFRIFRML$	228
CDK2	THEVVTLWYRAPEILLGSKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTL	219
CDK1	THEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRAL	220

CDK1	GTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKM 2	280
CDK2	GTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKA 2	279
CDK3	GTPSEDTWPGVTQLPDYKGSFPKWTRKGLEEIVPNLEPEGRDLLMQLLQYDPSQRITAKT 2	288
CDK4	GLPPEDDWPRDVSLPRGAFPPRGPRPVQSVVPEMEESGAQLLLEMLTFNPHKRISAFR 2	288
CDK7	GTPTEEQWPDMCSLPDYVT-FKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQ 2	288
	* * : ** .: *	

CDK1	ALNHPYFNDLDNQIKKM	297
CDK2	ALAHPFFQDVTKPVPHLRL	298
CDK3	ALAHPYFSSPE-PSPAARQYVLQRFRH	314
CDK4	ALQHSYLHKDEGNPE	303
CDK7	ALKMKYFSNRPGPTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF	347

**Figure S2**. The sequence alignments of CDK1, CDK2, CDK3, CDK4 and CDK7 generated by Clustal W. at http://www.ebi.ac.uk/Tools/msa/clustalw2/. In the sequences, an asterisk (\*) indicates an identical or conserved residue; a colon (:) indicates conserved substitutions; a stop (.) indicates semi-conserved substitutions.

Rank	Total energy		Volume (Å)		Residues contributing to each cluster			
	(kcal·mol <sup>-1</sup> )				(identified by subsite)			
	CDK2	CDK7	CDK2	CDK7	CDK2	CDK7		
1	-1622.97	-955.83	123	75	I10, G11, G13, V18, K33,	E20, T96, D97, E99,		
					V64, F80, Q131, N132, A144,	V100, K139, P140, N141		
					D145			
2	-797.57	-841.43	66	57	E8, K9, I10, G11, K20, F82,	L18, K41, F91, D92, F93,		
					H84	M94, E95, T96, D97,		
						L144, A154, D155		
3	-125.81	-561.12	8	50	I10, E81, F82, L83, A31,	F93, E95, T96, E147		
					L134			

**Table S2.** Result of binding site comparison of CDK2 and CDK7, based on EasyMIFs usingCMET probes.

**Table S3.** Quantum chemical descriptors based upon DFT calculations used for MESP forcompounds CP1, CP2, and CP3.

Quantum descriptors		Gas phase		Solvent phase (Aqueous)		
	CP1	CP2	CP3	CP1	CP2	CP3
$E_{\rm LUMO}~({\rm eV})$	-0.080	-0.105	-0.065	-0.071	-0.117	-0.067
$E_{\rm HOMO}~({\rm eV})$	-0.222	-0.215	-0.190	-0.217	-0.215	-0.188
Total dipole moment $\mu$ (D)	11.52	4.41	5.19	15.75	5.85	6.85



**Figure S3.** Molecular orbital for the HOMO–LUMO plot of (A) CP1, (B) CP2, and (C) CP3 with B3LYP/6-31G (d,p)



**Figure S4. (A)** The distance of CDK2-Asp145 (OD1) and CDK7-Asp155 (OD1) from C27 atom of inhibitor CP1, plotted as a function of time in CDK2-CP1 and CDK7-CP1. **(B)** The distance of CDK2-Asp86 (OD1) and CDK7-Asp97 (OD1) from N<sub>17</sub> atom of inhibitor CP2, plotted as a function of time in CDK2-CP2 and CDK7-CP2. **(C)** The distance of CDK2-Asp86 (CB) and CDK7-Asp97 (CB) from N<sub>6</sub> atom of inhibitor CP3, plotted as a function of time in CDK2-CP3 and CDK7-CP3.

System	Donor <sup>a</sup>	Acceptor <sup>a</sup>	Occupancy(%) <sup>b</sup>	Distance(Å) <sup>c</sup>	Angle(°) <sup>d</sup>
CDK2-CP1	Leu83 N-H	CP1 N1	98.48	$3.003 \pm 0.12$	24.90 ± 13.12
	CP1 N1-H9	Leu83 O	73.16	$2.999 \pm 0.17$	$27.15 \pm 8.12$
	Lys89 NZ-HZ3	CP1 O2	41.69	$3.234\pm0.45$	$33.05 \pm 15.12$
	Lys89 NZ-HZ2	CP1 O2	31.69	$3.202 \pm 0.60$	$33.53 \pm 14.87$
CDK7-CP1	CP1 N1-H9	MET94 O	99.97	$2.952 \pm 0.15$	$23.29 \pm 10.12$
	Met94 N-H	CP1 N1	99.28	$3.064 \pm 0.14$	$32.19 \pm 14.55$
	Lys44 NZ-HZ2	CP1 O3	36.00	$2.87\pm0.70$	$154.31 \pm 14.73$
CDK2- CP2	CP2 N7-H8	Leu83 O	99.81	$3.001 \pm 0.16$	$21.96 \pm 11.08$
	Leu83 N-H	CP2 N1	97.83	$3.099 \pm 0.15$	$29.01 \pm 13.13$
	CP2 N7A-H5	Asp145 OD1	46.28	$3.011\pm0.28$	$21.36 \pm 11.00$
	CP2 N7A-H4	Asp145 OD2	40.40	$3.454\pm0.59$	$32.67 \pm 14.69$
	Lys89 NZ-HZ2	CP2 O8B	12.80	$3.498\pm0.78$	$34.19 \pm 14.49$
CDK7-CP2	CP2 N7-H8	Met94 O	99.30	$2.961\pm0.15$	$19.31 \pm 11.30$
	Met94 N-H	CP2 N1	98.37	$3.106\pm0.15$	$28.58 \pm 12.97$
	CP2 N7A-H4	Asp155 OD2	30.59	$3.241\pm0.75$	$27.72 \pm 15.58$
	CP2 N7A-H4	Asp155 OD1	28.21	$4.142\pm0.72$	$37.56 \pm 13.74$
CDK2-CP3	CP3 N7-H6	Leu83 O	100	$3.026\pm0.16$	$27.77 \pm 13.07$
	Leu83 N-H	CP3 N1	99.80	$3.054\pm0.13$	$21.74\pm10.26$
CDK7-CP3	CP3 N7-H6	Leu83 O	99.94	$3.038\pm0.21$	$19.55 \pm 10.12$
	МЕТ94 N-Н	CP3 N1	99.51	$3.023\pm0.13$	$31.79 \pm 13.87$
Q85T- CP1	Leu83 N-H	CP1 N1	85.90	$3.090 \pm 0.16$	21.70 ± 9.69
K89L- CP1	Leu83 N-H	CP1 N1	82.97	$3.123 \pm 0.16$	$21.65 \pm 9.79$
	CP1 N8-H	Glu228 O	100	$2.63 \pm 0.11$	$158.97\pm9.88$
	CP1 N16-H	Asp292 OD2	30.00	$4.31\pm0.43$	$144.23 \pm 13.75$
D145A- CP1	Leu83 N-H	CP1 N1	79.69	$3.167 \pm 0.19$	21.65 ± 9.79

Table S4. Hydrogen bonds analyses from MD trajectories <sup>a</sup>

<sup>*a*</sup> The listed donor and acceptor pairs satisfy the criteria for the hydrogen bond over 30.0% of the time during the 40 ns of simulation. <sup>*b*</sup> Occupancy is in unit of percentage of the investigated time period. <sup>*c*</sup> The average distance with standard error (SE = standard deviation/N<sub>1/2</sub>) between hydrogen acceptor atom and proton on hydrogen donor atom in the investigated time period. <sup>*d*</sup> The average angle with standard error (SE = standard deviation/N<sub>1/2</sub>) in parentheses for hydrogen bond in the investigated time period.